COVID-19 Seroprevalence Study in ITM Staff

Severe Acute Respiratory Syndrome Coronavirus (CoV) 2 (SARS-CoV-2) Seroprevalence Study in Institute of Tropical Medicine (ITM) Staff

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04503447

Acronym

CovAb

Enrollment

330

Registered

2020-08-07

Start date

2020-08-01

Completion date

2020-09-09

Last updated

2020-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

humans, COVID-19, pandemics, SARS virus, cross-sectional studies, seroepidemiological studies, Belgium, risk factors, seroprevalence

Brief summary

In Belgium, the corona virus disease 2019 (COVID-19) epidemic is in the growing phase of its second wave. The Belgian crisis cell is balancing between allowing the economy to recover and minimize the disease spread. To decide which containment measures should be maintained, reinstalled or suspended, information on what proportion of people has been infected and on possible risk factors for virus transmission can be helpful. This study will be conducted on staff members of the ITM. All staff members will be invited to participate. Participants will be asked to have a blood sample drawn for detections of antibodies against SARS-CoV-2 (using one of these two commercial assays: Anti-SARS-CoV-2 ELISA (EUROIMMUN) or WANTAI SARS-CoV-2 Ab ELISA (WANTAI SARS-CoV-2 Diagnostics)) and to complete a questionnaire about their exposure, both within and outside the ITM, to the SARS-CoV-2, and about their health and symptoms. The primary objective is to estimate the occurrence rate of anti-SARS-CoV-2 antibodies or seroprevalence in ITM staff. Secondary objective is to estimate the SARS-CoV-2 seroprevalence in ITM staff member groups, stratified by variables obtained through the questionnaire, such as age, gender, symptoms, exposure to COVID-19 patients/samples, comorbidities, adherence to containment measures.

Detailed description

The study is observational and will be conducted on ITM staff members. All members will be invited to participate.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Inclusion criteria

* Be an active ITM staff member * Be willing and able to complete the questionnaire * Be willing and able to provide informed consent

Exclusion criteria

* Doctor of Philosophy (PhD) students, Master students and interns of the ITM

Design outcomes

Primary

Measure	Time frame	Description
SARS-CoV-2 seroprevalence ITM staff	Sample is drawn once, within 7 days after recruitment	The proportion of participating ITM staff members with detectable SARS-CoV-2 antibodies

Secondary

Measure	Time frame	Description
SARS-CoV-2 seroprevalence in ITM staff, stratified by variables	Questionnaire is completed once, at recruitment	SARS-CoV-2 seroprevalence in ITM staff members stratified by variables obtained through the questionnaire, such as age, gender, symptoms, exposure to COVID-19 patients/samples, comorbidities, adherence to containment measures.

Other

Measure	Time frame	Description
Risk or protective factors for SARS-CoV-2 seropositivity	Questionnaire is completed once, at recruitment	To identify factors that are associated with an elevated or reduced risk of seropositivity in ITM staff and the Belgian working population in general.

Countries

Belgium

Outcome results